{'52WeekChange': -0.27465218,
 'SandP52WeekChange': 0.0644362,
 'address1': '28 Liberty Street',
 'address2': '39th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.9,
 'askSize': 800,
 'averageDailyVolume10Day': 104462,
 'averageVolume': 140314,
 'averageVolume10days': 104462,
 'beta': 1.146375,
 'beta3Year': None,
 'bid': 11.8,
 'bidSize': 800,
 'bookValue': 0.634,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.8101,
 'dayLow': 11.97,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.416,
 'enterpriseToRevenue': None,
 'enterpriseValue': 313764992,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '646 219 9660',
 'fiftyDayAverage': 15.442286,
 'fiftyTwoWeekHigh': 23,
 'fiftyTwoWeekLow': 9.38,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14894628,
 'forwardEps': -2.85,
 'forwardPE': -4.2070174,
 'fromCurrency': None,
 'fullTimeEmployees': 61,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.68432,
 'heldPercentInstitutions': 0.07326,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/beyondspringpharma.com',
 'longBusinessSummary': 'BeyondSpring Inc., a clinical stage biopharmaceutical '
                        'company, together with its subsidiaries, focuses on '
                        'the development and commercialization of '
                        "immuno-oncology cancer therapies. The company's lead "
                        'asset is the Plinabulin that is in late stage '
                        'clinical trials as an anti-cancer agent in '
                        'combination with docetaxel in advanced non-small cell '
                        'lung cancer (NSCLC) for the prevention of high and '
                        'intermediate risk chemotherapy-induced neutropenia. '
                        'It is also developing Plinabulin in combination with '
                        'various immuno-oncology agents, including nivolumab, '
                        'a programmed cell death protein 1 antibody for the '
                        'treatment of NSCLC; nivolumab and ipilimumab, a '
                        'CTLA-4 antibody to treat small cell lung cancer; and '
                        'death protein 1 or programmed death-ligand 1, an '
                        'antibodies and radiation or chemotherapy for the '
                        'treatment of multiple cancers. In addition, the '
                        'company engages in the development of three small '
                        'molecule immune agents in preclinical stages; and a '
                        'drug development platform using ubiquitin mediated '
                        'protein degradation pathway. BeyondSpring Inc. has '
                        'collaboration agreements with the Fred Hutchinson '
                        'Cancer Research Center and the University of '
                        'Washington. The company was founded in 2010 and is '
                        'headquartered in New York, New York.',
 'longName': 'BeyondSpring Inc.',
 'market': 'us_market',
 'marketCap': 360999712,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_409784135',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -46876000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.75,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646 305 6387',
 'previousClose': 12.78,
 'priceHint': 2,
 'priceToBook': 18.91167,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.8101,
 'regularMarketDayLow': 11.97,
 'regularMarketOpen': 12.75,
 'regularMarketPreviousClose': 12.78,
 'regularMarketPrice': 12.75,
 'regularMarketVolume': 110406,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 30108400,
 'sharesPercentSharesOut': 0.0249,
 'sharesShort': 748756,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 575357,
 'shortName': 'BeyondSpring, Inc.',
 'shortPercentOfFloat': 0.0402,
 'shortRatio': 2.75,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'BYSI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.815,
 'twoHundredDayAverage': 15.182518,
 'volume': 110406,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.beyondspringpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10005'}